Legend Biotech Corp Adjustments For Decrease Increase In Trade Account Receivable
Legend Biotech Corp (LEGN) reported Adjustments For Decrease Increase In Trade Account Receivable of -$5.70 million for the 12-month period ending 2025-12-31, per its 20-F filed 2026-03-10.
Financial Statements › Notes › Receivables
ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable · last filed 2026-03-10
- Legend Biotech Corp adjustments for decrease increase in trade account receivable for the quarter ending 2025-12-31 was -$11.21M.
- Legend Biotech Corp adjustments for decrease increase in trade account receivable for the quarter ending 2025-09-30 was $25.79M, a 108.67% increase year-over-year.
- Legend Biotech Corp adjustments for decrease increase in trade account receivable for the quarter ending 2025-06-30 was -$26.20M.
- Legend Biotech Corp adjustments for decrease increase in trade account receivable for the quarter ending 2025-03-31 was $5.92M, a 93.88% decline year-over-year.
| Period end | Adjustments For Decrease Increase In Trade Account Receivable 3 month | Adjustments For Decrease Increase In Trade Account Receivable 6 month | Adjustments For Decrease Increase In Trade Account Receivable 9 month | Adjustments For Decrease Increase In Trade Account Receivable 12 month | Adjustments For Decrease Increase In Trade Account Receivable 12 month as first filed |
|---|---|---|---|---|---|
| 2025-12-31 | -$11.21M derived: 20-F 12 month − 6-K 9 month · filed 2026-03-10 | $14.58M derived: sum of 2 quarters · filed 2026-03-10 | -$11.62M derived: sum of 3 quarters · filed 2026-03-10 | -$5.70M 20-F · filed 2026-03-10 | |
| 2025-09-30 | $25.79M derived: 6-K 9 month − 6-K 6 month · filed 2025-11-12 | -$408.00K derived: sum of 2 quarters · filed 2025-11-12 | $5.51M 6-K · filed 2025-11-12 | -$26.00K derived: sum of 4 quarters · filed 2026-03-10 | |
| 2025-06-30 | -$26.20M derived: 6-K 6 month − 6-K 3 month · filed 2025-08-11 | -$20.28M 6-K · filed 2025-08-11 | -$25.82M derived: sum of 3 quarters · filed 2026-03-10 | -$13.46M derived: sum of 4 quarters · filed 2026-03-10 | |
| 2025-03-31 | $5.92M 6-K · filed 2025-05-13 | $382.00K derived: sum of 2 quarters · filed 2026-03-10 | $12.74M derived: sum of 3 quarters · filed 2026-03-10 | $2.98M derived: sum of 4 quarters · filed 2026-03-10 | |
| 2024-12-31 | -$5.54M derived: 20-F 12 month − 6-K 9 month · filed 2026-03-10 | $6.82M derived: sum of 2 quarters · filed 2026-03-10 | -$2.93M derived: sum of 3 quarters · filed 2026-03-10 | $93.80M 20-F · filed 2026-03-10 | $93.75M 20-F · filed 2025-03-11 |
| 2024-09-30 | $12.36M derived: 6-K 9 month − 6-K 6 month · filed 2025-11-12 | $2.60M derived: sum of 2 quarters · filed 2025-11-12 | $99.34M 6-K · filed 2025-11-12 | $266.00K derived: sum of 4 quarters · filed 2026-03-10 | |
| 2024-06-30 | -$9.76M derived: 6-K 6 month − 6-K 3 month · filed 2025-08-11 | $86.98M 6-K · filed 2025-08-11 | -$12.09M derived: sum of 3 quarters · filed 2026-03-10 | $2.95M derived: sum of 4 quarters · filed 2026-03-10 | |
| 2024-03-31 | $96.73M 6-K · filed 2025-05-13 | -$2.34M derived: sum of 2 quarters · filed 2026-03-10 | $12.71M derived: sum of 3 quarters · filed 2026-03-10 | -$2.30M derived: sum of 4 quarters · filed 2026-03-10 | |
| 2023-12-31 | -$99.07M derived: 20-F 12 month − 6-K 9 month · filed 2026-03-10 | -$84.03M derived: sum of 2 quarters · filed 2026-03-10 | -$99.03M derived: sum of 3 quarters · filed 2026-03-10 | -$99.00M 20-F · filed 2026-03-10 | -$98.98M 20-F · filed 2024-03-19 |
| 2023-09-30 | $15.04M derived: 6-K 9 month − 6-K 6 month · filed 2024-11-12 | $36.00K derived: sum of 2 quarters · filed 2024-11-12 | $70.00K 6-K · filed 2024-11-12 | $39.00K derived: sum of 4 quarters · filed 2025-03-11 | |
| 2023-06-30 | -$15.01M derived: 6-K 6 month − 6-K 3 month · filed 2024-08-09 | -$14.97M 6-K · filed 2024-08-09 | -$15.01M derived: sum of 3 quarters · filed 2025-03-11 | -$14.60M derived: sum of 4 quarters · filed 2025-03-11 | |
| 2023-03-31 | $34.00K 6-K · filed 2024-05-13 | $3.00K derived: sum of 2 quarters · filed 2025-03-11 | $406.00K derived: sum of 3 quarters · filed 2025-03-11 | ||
| 2022-12-31 | -$31.00K derived: 20-F 12 month − 6-K 9 month · filed 2025-03-11 | $372.00K derived: sum of 2 quarters · filed 2025-03-11 | $50.32M 20-F · filed 2025-03-11 | ||
| 2022-09-30 | $403.00K derived: 6-K 9 month − 6-K 6 month · filed 2023-11-20 | $50.35M 6-K · filed 2023-11-20 | |||
| 2022-06-30 | $49.95M 6-K · filed 2023-08-15 | ||||
| 2021-12-31 | $24.59M 20-F · filed 2024-03-19 | ||||
| 2021-06-30 | $60.00M 6-K · filed 2021-08-23 | ||||
| 2020-12-31 | -$45.00M 20-F · filed 2023-03-30 | ||||
| 2020-06-30 | $30.00M 6-K · filed 2021-08-23 | ||||
| 2019-12-31 | $21.23M 20-F/A · filed 2023-02-17 | -$3.77M 20-F · filed 2021-04-02 | |||
| 2018-12-31 | $207.61M 20-F · filed 2021-04-02 |